Antibody/Targeted-Drug Conjugates 2017

22-24 March 2017, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 22nd March 2017

08.00
Arrival & Registration

09.00
Opening Remarks

SESSION 1:
OPENING PLENARY SESSION

Moderator: John A. Flygare (Merck Inc., USA)

09.00-09.45
‘Biology and engineering of Cow ultralong CDR3 antibodies’

Vaughn Smider (Sevion Therapeutics, San Diego, California, USA)

09.45-10.30
‘The development of antibody pyrrolobenzodiazepine conjugates’

Philip Howard (MedImmune/Spirogen Ltd, London, UK)

10.30-11.00
Coffee Break & Posters

SESSION 2:
PLENARY

Moderator: Roger R. Beerli (NBE-Therapeutics Ltd., Basel, Switzerland)

11.00-11.45
‘Pre-clinical development of a Flt3 specific ADC (AGS62P1) for the treatment of acute myeloid leukemia (AML) utilizing site specific conjugation and a novel, potent, tubulin inhibiting payload’

Kendall Morrison (Agensys Inc., Santa Monica, California, USA)

11.45-12.30
‘Update on mirvetuximab soravtansine and ImmunoGen’s growing ADC pipeline’

John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)

12.30-12.45
Moderator-led Session Discussion

12.45-14.00
Lunch Break & Posters

SESSION 3:
CONJUGATION

Moderator: John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)

14.00-14.30
‘Development on novel bioconjugation technologies for ADCs’

Vijay Chudasama (University College London, London, UK)

14.30-15.00
‘Highly potent, anthracycline-based ADCs generated by enzymatic, site-specific conjugation’

Roger R. Beerli (NBE-Therapeutics Ltd., Basel, Switzerland)

15.00-15.30
‘Moving a chemo-enzymatic protein conjugation technology from benchtop to large scale production’

Gregory Bleck (Catalent Pharma Solutions, Somerset, New Jersey, USA)

15.30-15.45
Moderator-led Session Discussion

15.45-16.15
Tea Break & Posters

SESSION 4:
ANTIBODY DRUG CONJUGATES

Moderator: David Rabuka (Catalent Pharma Solutions, Somerset, New Jersey, USA)

16.15-16.45
‘A novel platinum (II)-based bifunctional ADC linker benchmarked using 89Zr-Desferal and Auristatin F conjugated Trastuzumab’

Eugen Merkul (LinXis Pharmaceuticals, Amsterdam, The Netherlands)

16.45-17.15
‘Enabling better Antibody Drug Conjugates’
Campbell Bunce and George Badescu (Abzena PLC, Cambridge, UK)

17.15-17.45
‘Glycan-conjugated ADCs come with significantly expanded therapeutic index compared to both marketed ADCs’

Floris van Delft, Brian Janssen, Inge Hurkmans, Remon van Geel, Jorge Verkade, Jorin Hoogenboom, Marloes, Wijdeven and Sander van Berkel (Synaffix BV, Oss, The Netherlands)

17.45-18.00
Moderator-led Session Discussion

18.00-19.00
ATDC 2017 Welcome Drinks Reception & Posters

 

ATDC 2017 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2017 Sponsors

  • Catalent
  • NatureGeneTherapy.com
  • ONdrugDelivery
  • ADC Review
  • Aldevron
  • Genentech
  • Genovis
  • Oncozine
  • Pfizer Oncology
  • Lonza
  • ImmunoGen
  • LinXis
  • Cancer Targeting Solutions Consultancy
  • Sutro BioPharma
  • NBE Therapeutics

ATDC 2017 Downloads

ATDC 2017 Leaflet

ATDC 2017 Mailing List

Name
E-mail Address
What is 3+2-1?